CERE Investors Have Opportunity to Lead Cerevel Therapeutics Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Provided By PR Newswire

Last update: Apr 24, 2025

LOS ANGELES, April 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ: CERE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.